MSH5 and type 1 diabetes mellitus: Considering the costs of CD-specific serological tests which should be frequently performed in T1D patients, the screening algorithm, including combination of the MSH5 variant and specific celiac HLA SNPs, and then serological testing only the genetically selected risk group seems to be cost-effective.